Isoniazid is an important antitubercular molecule identified as a drug of choice in tuberculosis treatment. As such, INH is an inactive prodrug; it acquires an active conformation by forming an adduct
Background The therapeutic use of monoclonal antibodies (mAbs) has significantly increased since the first mAb was introduced. Despite their therapeutic benefits, mAbs have been accompanied by a rise